Your browser is no longer supported. Please, upgrade your browser.
UroGen Pharma Ltd.
Index- P/E- EPS (ttm)-5.91 Insider Own2.20% Shs Outstand22.15M Perf Week-2.47%
Market Cap400.97M Forward P/E- EPS next Y-2.94 Insider Trans1.64% Shs Float19.36M Perf Month3.89%
Income-128.50M PEG- EPS next Q-1.29 Inst Own75.50% Short Float12.09% Perf Quarter-32.64%
Sales11.80M P/S33.98 EPS this Y-15.20% Inst Trans2.61% Short Ratio13.27 Perf Half Y-27.04%
Book/sh4.35 P/B4.17 EPS next Y39.50% ROA-87.10% Target Price- Perf Year-25.39%
Cash/sh4.62 P/C3.93 EPS next 5Y- ROE-100.80% 52W Range17.00 - 30.89 Perf YTD0.78%
Dividend- P/FCF- EPS past 5Y-36.70% ROI-135.00% 52W High-41.21% Beta1.20
Dividend %- Quick Ratio5.30 Sales past 5Y- Gross Margin91.40% 52W Low6.82% ATR1.10
Employees187 Current Ratio5.40 Sales Q/Q- Oper. Margin- RSI (14)42.84 Volatility7.21% 5.99%
OptionableYes Debt/Eq0.00 EPS Q/Q25.80% Profit Margin- Rel Volume0.54 Prev Close17.99
ShortableYes LT Debt/Eq0.00 EarningsMay 13 BMO Payout- Avg Volume176.29K Price18.16
Recom1.70 SMA20-4.77% SMA50-5.39% SMA200-13.60% Volume96,487 Change0.94%
Apr-16-20Reiterated H.C. Wainwright Buy $53 → $57
Apr-13-20Reiterated H.C. Wainwright Buy $75 → $53
Jan-09-20Initiated National Securities Neutral $37
May-30-19Initiated JP Morgan Neutral
May-29-19Initiated Goldman Neutral
Jan-29-19Initiated H.C. Wainwright Buy $82
Nov-08-18Resumed Jefferies Buy
Apr-04-18Upgrade Raymond James Mkt Perform → Outperform
Jan-02-18Initiated Ladenburg Thalmann Buy $50
Nov-15-17Reiterated Oppenheimer Outperform $32 → $51
Nov-15-17Downgrade Raymond James Outperform → Mkt Perform
May-13-21 07:30AM  
May-12-21 08:11AM  
May-06-21 08:00AM  
Mar-18-21 09:15AM  
Mar-15-21 08:00AM  
Mar-12-21 04:44AM  
Mar-11-21 08:00AM  
Mar-05-21 08:00AM  
Feb-23-21 08:00AM  
Jan-26-21 07:01AM  
Jan-19-21 07:00AM  
Jan-13-21 08:00AM  
Jan-06-21 08:00AM  
Dec-18-20 04:36AM  
Dec-16-20 07:20AM  
Dec-11-20 08:35AM  
Dec-07-20 07:00AM  
Dec-04-20 08:42AM  
Dec-03-20 08:00AM  
Nov-29-20 07:57PM  
Nov-17-20 08:00AM  
Nov-12-20 08:00AM  
Nov-11-20 08:00AM  
Nov-10-20 08:00AM  
Nov-09-20 07:00PM  
Nov-02-20 08:00AM  
Oct-27-20 06:50AM  
Oct-07-20 12:58PM  
Oct-05-20 08:00AM  
Sep-15-20 12:14PM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Sep-04-20 08:00AM  
Aug-27-20 08:00AM  
Aug-10-20 05:00PM  
Aug-03-20 08:00AM  
Jun-15-20 08:43PM  
Jun-05-20 08:00AM  
Jun-01-20 08:00AM  
May-15-20 09:01AM  
May-09-20 02:31PM  
May-07-20 08:00AM  
May-01-20 08:00AM  
Apr-30-20 09:05AM  
Apr-21-20 12:34PM  
Apr-16-20 10:37AM  
Apr-15-20 06:22PM  
Apr-06-20 08:53AM  
Apr-03-20 08:00AM  
Mar-23-20 08:00AM  
Mar-16-20 11:45AM  
Mar-06-20 08:00AM  
Mar-02-20 08:00AM  
Feb-25-20 08:00AM  
Feb-24-20 08:00AM  
Jan-30-20 08:59AM  
Jan-08-20 08:00AM  
Dec-19-19 08:00AM  
Dec-17-19 07:36PM  
Dec-16-19 12:00PM  
Dec-06-19 08:00AM  
Dec-01-19 03:06PM  
Nov-18-19 08:00AM  
Nov-12-19 08:00AM  
Nov-11-19 08:00AM  
Nov-06-19 10:16AM  
Sep-30-19 08:00AM  
Sep-24-19 04:01PM  
Sep-18-19 12:15PM  
Sep-10-19 08:00AM  
Sep-06-19 04:05PM  
Aug-13-19 03:05PM  
Aug-12-19 04:23PM  
Aug-10-19 07:11AM  
Aug-09-19 08:00AM  
Aug-05-19 08:00AM  
Jul-23-19 10:43AM  
Jul-16-19 09:48AM  
Jul-05-19 05:14PM  
Jul-01-19 08:00AM  
May-30-19 08:00AM  
May-26-19 08:18AM  
May-20-19 12:48PM  
UroGen Pharma Ltd., a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. It also has a strategic research agreement with the Johns Hopkins University to explore the potential of checkpoint inhibitors combined with RTGel in glioblastoma multiform. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schoenberg MarkChief Medical OfficerApr 30Sale20.002434,86021,132May 04 01:58 PM
Schoenberg MarkChief Medical OfficerApr 26Sale19.63891,74720,875Apr 27 01:44 PM
Belldegrun ArieDirectorMar 24Option Exercise5.003,24116,205245,452Apr 22 05:19 PM
Nussbaum RanDirectorMar 24Option Exercise5.001,0305,1501,465,199Apr 22 05:18 PM
Schoenberg MarkChief Medical OfficerJan 31Sale22.071,07623,74720,755Feb 02 02:53 PM
Schoenberg MarkChief Medical OfficerJan 26Sale22.121002,21219,831Jan 26 05:20 PM
Barrett Elizabeth A.Chief Executive OfficerDec 14Buy18.5010,000185,000229,117Dec 15 05:27 PM
Barrett Elizabeth A.Chief Executive OfficerDec 04Option Exercise0.0061,6520219,117Dec 04 04:35 PM
Schoenberg MarkChief Medical OfficerDec 04Sale19.8566213,14119,723Dec 07 03:59 PM
Schoenberg MarkChief Medical OfficerOct 26Sale20.951012,11619,343Oct 28 02:12 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerOct 15Sale21.772,40052,24810,405Oct 16 03:41 PM
Schoenberg MarkChief Medical OfficerSep 04Sale20.203487,03019,236Sep 08 04:48 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerSep 01Sale22.8250911,6157,888Sep 01 02:37 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerJul 27Sale23.511413,3157,355Jul 28 05:34 PM
Schoenberg MarkChief Medical OfficerJul 27Sale23.51701,64618,543Jul 28 05:32 PM
Schoenberg MarkChief Medical OfficerJun 04Sale27.513499,60218,404Jun 05 02:31 PM
PFREUNDSCHUH PETER P.Chief Financial OfficerMay 20Sale25.073588,9757,079May 20 04:44 PM